YM150
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Venous Thromboembolism
Conditions
Venous Thromboembolism
Trial Timeline
Jun 1, 2009 → Apr 1, 2010
NCT ID
NCT00942435About YM150
YM150 is a phase 3 stage product being developed by Astellas Pharma for Venous Thromboembolism. The current trial status is completed. This product is registered under clinical trial identifier NCT00942435. Target conditions include Venous Thromboembolism.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01125670 | Phase 1 | Completed |
| NCT01125657 | Phase 1 | Completed |
| NCT01118559 | Phase 1 | Completed |
| NCT00937820 | Phase 3 | Completed |
| NCT00937911 | Phase 3 | Completed |
| NCT00942435 | Phase 3 | Completed |
| NCT01028950 | Phase 3 | Completed |
| NCT01657981 | Phase 1 | Completed |
| NCT00353678 | Phase 2 | Completed |
Competing Products
20 competing products in Venous Thromboembolism